$9.14
-0.03[-0.33%]
At close: Apr 25
$9.14
0[0.00%]
After Hours: 4:20PM EDT
Theravance Biopharma
(NASDAQ:TBPH)Latest News for Theravance Biopharma Stock (NASDAQ:TBPH)
Theravance Biopharma Stock (NASDAQ: TBPH)
Categories: All
Friday, April 12, 2024
- Theravance Biopharma shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and a $21 price target.Benzinga Newsdesk - Apr 12, 2024, 11:28AM
- BTIG Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $21Benzinga Newsdesk - Apr 12, 2024, 7:42AM
Monday, February 26, 2024
- Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024Benzinga Newsdesk - Feb 26, 2024, 4:27PM
- Recap: Theravance Biopharma Q4 EarningsBenzinga Insights - Feb 26, 2024, 4:10PM
- Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M EstimateBenzinga Newsdesk - Feb 26, 2024, 4:08PM
- Earnings Scheduled For February 26, 2024Benzinga Insights - Feb 26, 2024, 4:47AM
Friday, February 23, 2024
Tuesday, January 23, 2024
Tuesday, January 16, 2024
Friday, January 05, 2024
- Theravance Biopharma shares are trading lower after the company announced results from the Phase 4 YUPELRI PIFR-2 study and said its endpoint did not show a statistically significant difference.Benzinga Newsdesk - Jan 5, 2024, 3:32PM
- Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Jan 5, 2024, 1:13PM
- Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?Vandana Singh - Jan 5, 2024, 10:36AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Jan 5, 2024, 8:05AM
- Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market SessionAvi Kapoor - Jan 5, 2024, 6:19AM
- Theravance Biopharma Announces Results From Phase 4 YUPELRI PIFR-2 Study, Says Study Did Not Show A Statistically Significant Difference Between Yupelri And Spiriva Handihaler On Primary EndpointBenzinga Newsdesk - Jan 5, 2024, 6:05AM
Thursday, December 28, 2023
Thursday, November 16, 2023
Monday, November 13, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
Monday, October 30, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
Friday, September 15, 2023
Monday, August 28, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
- UPDATE: Theravance Biopharma Q2 Adj EPS $(0.13) Beats $(0.16) Estimate, Sales $13.75M Miss $15.24M EstimateBenzinga Newsdesk - Aug 7, 2023, 5:11PM
- Theravance Biopharma Q2 Adj $(0.13) Beats $(0.16) Estimate, Sales $13.75M Miss $15.24M EstimateBenzinga Newsdesk - Aug 7, 2023, 4:39PM
- Earnings Scheduled For August 7, 2023Benzinga Insights - Aug 7, 2023, 4:12AM
Friday, August 04, 2023
Thursday, May 11, 2023
Tuesday, May 09, 2023
- Theravance Says Orphan Drug Designation Granted To Ampreloxetine For Treatment Of Symptomatic Neurogenic Orthostatic Hypotension In Patients With Multiple System AtrophyBenzinga Newsdesk - May 9, 2023, 6:02PM
- Theravance Biopharma Ireland Limited Granted Orphan Designation Status For Ampreloxetine For The Treatment Of Symptomatic Neurogenic Orthostatic Hypotension In Patients With Multiple System AtrophyHappy Mohamed - May 9, 2023, 12:05PM
- HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20Benzinga Newsdesk - May 9, 2023, 6:40AM
Monday, May 08, 2023
Wednesday, April 19, 2023
Wednesday, April 12, 2023
Tuesday, February 28, 2023
Monday, February 27, 2023
- UPDATE: Theravance Biopharma Q4 Adj. EPS $(0.21) Misses $(0.17) Estimate, Sales $14.65M Miss $15.73M EstimateHappy Mohamed - Feb 27, 2023, 8:18PM
- Theravance Biopharma Q4 EPS $(0.21) Misses $(0.17) Estimate, Sales $14.65M Miss $15.73M EstimateBenzinga Newsdesk - Feb 27, 2023, 4:29PM
- Theravance Biopharma Sees FY23 R&D Expense Of $35M-$45M And SG&A Expense Of $45M-$55MHappy Mohamed - Feb 27, 2023, 4:27PM
- Irenic Sends Letter To Theravance Biopharma Regarding The Urgent Need For A Governance Overhaul, Capital Return And Strategic ReviewBenzinga Newsdesk - Feb 27, 2023, 9:01AM
- Earnings Scheduled For February 27, 2023Benzinga Insights - Feb 27, 2023, 4:46AM